Module 4: Ocular Toxicity Studies: Why, When, and How to Conduct?
Recorded On: 05/22/2025
Ocular toxicity studies of small molecules, biotherapeutics, oligonucleotides, and gene therapies by various routes of administration usually cause adverse ocular effects, especially for intraocular routes (intravitreal, subretinal, intracameral, and suprachoroidal) and less so for the topical ocular route. One critical aspect of ocular toxicity studies is the importance of correlating pathology findings with in-life findings by standard and specialized ophthalmic techniques to guide mitigation and monitoring for ocular adverse events in clinical trials. The advent of ocular sustained-release formulations adds another layer of complexity to identifying ocular effects related to the formulation versus the drug. The contribution of adverse injection procedure-related effects can confound interpretation but does not usually factor into NOAEL determinations. Ocular biotherapeutics and gene therapy drugs are usually immunogenic via innate and/or adaptive responses that may or may not be relevant for human risk assessment. This module will discuss various ocular toxicity studies with practical principles that illustrate the challenges encountered and approaches needed for effective risk assessment and regulatory success with ocular drug development case studies.
Brian Short, DVM, PhD, DACVP
Consultant
Brian Short Consulting, LLC
Dr. Brian Short is a board-certified pathologist with a focus on ocular toxicology, pathology, and ocular drug development. Previously, he was at Allergan (currently AbbVie) as Senior Director of Toxicology and then Pathology following his early career at GlaxoSmithKline (formerly SmithKline Beecham). As an independent consultant since 2016, Dr. Short has consulted on over 160 projects involving ocular drug development of small molecules, biologics, oligonucleotides, and gene and cell therapies, or ocular toxicity of systemic small molecules and biologics. He has authored several seminal publications on ocular toxicology and pathology, served as an invited speaker for over 20 presentations on ocular drug development, and was honored in 2021 with a Career Achievement Award by the Ocular Toxicology Specialty Section of SOT. Currently, Dr. Short is Chair of the Ocular Adversity Working Group sponsored by the STP Scientific and Regulatory Policy Committee. Dr. Short has a DVM from the University of California, Davis; completed a Veterinary Pathology Residency at the University of Florida, Gainesville; earned a PhD in Experimental Pathology from the University of North Carolina, Chapel Hill; and was a Postdoctoral Trainee at the Chemical Industry Institute of Toxicology in Research Triangle Park, NC.